Redmile Group, LLC

CIK 0001425738

2 SPACs with a current declared position, filed between Feb 14, 2022 and Mar 13, 2024. 0 of them were re-affirmed in the last 12 months. The rest are the filer’s last word on a position, not proof it is still held: an amendment is only required on a material change, so a fund that sells below 5% may never file again.

This filer has not filed a Schedule 13 on any SPAC since Mar 13, 2024. Read the page below as a record of what was declared, not as a register of what is held.

SPACs declared

every position whose latest statement stands — the record

Re-affirmed in 12 months

filed inside 365 days — what a reader means by "owns"

Still live

positions in SPACs still searching or in an announced deal

Median stake

0.0%

no percentage stated on the cover pages

1 passive (13G)1 activist (13D)14 superseded statements on file

Positions

one row per SPAC — every figure read from the accession in the Source column

2 of 2 shown · 2 positions have not been amended in over a year

	SPAC			Voting	Dispositive			Source
DYNS	Senti Biosciences Holdings, Inc.3 reporting persons on this schedule	0.0%	0	0 / 0	0 / 0	Closed (deSPAC)	Feb 14, 2022Stale	SC 13G/A0001104659-22-023151 3 earlier statements
LSAQ	Lifesci Acquisition II Corp.4 reporting persons on this schedule	0.0%	0	0 / 0	0 / 0	Closed (deSPAC)	Mar 13, 2024Stale	SC 13D/A · may seek to influence control0001104659-24-034010 11 earlier statements

14 superseded statements (newest 4 shown)

An amendment replaces a stake as current; it never erases the record of it. These are the earlier statements, each with the accession that replaced it — kept because “what did this filer say in 2022” is a different question from “what does it say now”, and only the second one has an answer above.

LSAQ Lifesci Acquisition II Corp.16.5% · SC 13D/A Jan 31, 2024replaced Mar 13, 2024 by 0001104659-24-034010
LSAQ Lifesci Acquisition II Corp.17.1% · SC 13D/A Jun 15, 2022replaced Jan 31, 2024 by 0001104659-24-008882
LSAQ Lifesci Acquisition II Corp.17.3% · SC 13D Oct 18, 2021replaced Jun 15, 2022 by 0001104659-22-071497
DYNS Senti Biosciences Holdings, Inc.8.5% · SC 13G Jun 7, 2021replaced Feb 14, 2022 by 0001104659-22-023151

Reporting persons on this filer's schedules

one filer, several names — collapsed once, shown in full

A joint Schedule 13 names every person who beneficially owns the shares — the management company, the funds it advises, the general partner and often the individual who controls all three. They report the same shares. Counting them separately would publish this filer’s footprint two or three times over, so they are counted once, under CIK 0001425738. This filer has named 5 of them across the schedules in the table above:

Jeremy C. Green
RedCo II Master Fund
Redmile Capital Offshore Master Fund
Redmile Group
Redmile Private Investments II

Appears alongside

other filers with a current declared position in the same SPACs

Co-occurrence in the disclosure record, and nothing more. It is not evidence of a group, an agreement or acting in concert — filers who act as a group say so on the cover page and file a 13D. Two arbitrage funds above 5% in the same shell is the ordinary shape of this market. The second number restricts both sides to statements filed in the last 12 months, because a 2021 stake beside a 2026 one is two facts about two different years.

Every percentage above is the one printed on the cover page of the filing cited beside it — a percentage of the shares outstanding on that date. A SPAC’s float collapses at each redemption, so two of these percentages are percentages of two different companies and they do not add. Rows are one per SPAC: where a joint schedule names several reporting persons, the largest single figure is shown rather than their sum, because a manager and the funds it advises beneficially own the same shares. Nothing on this page is derived from a 13F, a vendor holdings file or a press release. See how this is built.